GlassScriptPhysician profile
Cheyanne Smith
NPI 1306677513
$938.21
in general payments reported to CMS, 2019-2025
11 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $150 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.82 | 2025 | Lifevest |
| Novo Nordisk INC | $140.83 | 2024-2025 | Wegovy |
| Cvrx, INC. | $122.01 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $91.80 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.39 | 2025 | Jardiance |
| Pfizer INC. | $68.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.31 | 2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $51.48 | 2025 | Verquvo |
| Scpharmaceuticals INC. | $50.09 | 2025 | |
| Cranial Technologies, INC | $14.84 | 2024 | Doc Band |
| Amgen INC. | $13.59 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyanne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.